The commentary of Newman et al1 regarding recommendations for lipid screening in childhood from the expert panel guidelines commissioned by the National Heart Lung and Blood Institute2,3 misrepresents the evidence regarding screening and the specificity and rigor of the guideline development process. The expert panel developed comprehensive, integrated, and evidence-based guidelines for promotion of cardiovascular (CV) health and the identification and management of specific risk factors from infancy into young adulthood. The large, diverse, and complex evidence base that addresses CV risk beginning in childhood, and the absence of decades long event-driven clinical trials, required consideration of substantial and consistent evidence from observational studies, developing a chain of evidence. A priori, a systematic process was used to review and grade the evidence and develop the recommendations, which is explicitly described in the Full3 and Summary Reports,2 and the evidence tables are available on the...
Guidelines for Lipid Screening in Children and Adolescents: Bringing Evidence to the Debate
FINANCIAL DISCLOSURE: Dr McCrindle is a consultant to or advisory board member at Genzyme (Sanofi), Merck, and Abbott; a data and safety monitoring board member at Medpace; and receives research funding from Schering Plough, Astra Zeneca, and the National Institutes of Health. Dr Kwiterovich is a consultant to or advisory board member at Merck, LipoScience, and Genzyme; he receives research funding from Pfizer. The other authors have indicated they have no financial relationships relevant to this article to disclose.
- Views Icon Views
- Share Icon Share
- Search Site
Brian W. McCrindle, Peter O. Kwiterovich, Patrick E. McBride, Stephen R. Daniels, Rae-Ellen W. Kavey; Guidelines for Lipid Screening in Children and Adolescents: Bringing Evidence to the Debate. Pediatrics August 2012; 130 (2): 353–356. 10.1542/peds.2012-1137
Download citation file: